Page 2,044«..1020..2,0432,0442,0452,046..2,0502,060..»

Category Archives: Transhuman News

Biotech: Full steam ahead on several scientific fronts – The San Diego Union-Tribune

Posted: February 20, 2017 at 6:47 pm

Where do you see San Diego's biotech/life sciences tech sector headed in 2017?

2017 will bring us skyrocketing advancements in genomics. In fact, it is already happening on several fronts. We know that Illumina is the behemoth in sequencing, and is a company that has put San Diego on the world map. Now, we are considered the global epicenter in sequencing. With Illumina's additional focus on oncology, we have the perfect pairing with another of San Diego's strengths: big data computation. Companies like Helix have recently begun operations in mass-sample sequencing, Edico Genomics and others are revolutionizing the way genetic data is analyzed, and Human Longevity is using genetic data to deliver personalized health solutions. There are dozens of such companies in the region that are fueling innovation for the coming year.

Additionally, the field of personalized medicine, especially as it relates to the device and wireless health side, is well positioned for continued growth. We are fortunate to have a telecommunications sector that evolved here alongside our medical device sector. That pairing is paying off today in the form of transformative companies such as Dexcom, with its advanced continuous glucose monitoring and dosing technology, and Qualcomm Life, with its platform that enhances clinical workflows and operational efficiencies in the hospital; both are widely recognized global leaders. I am eager to hear from companies on the continued development in this promising sector as it provides tangible results in terms of greater efficiency and lower cost of health care.

Where do you see biggest growth?

We have more than 120 oncology research and development companies working here in nearly every type of known cancer. We recently created an Oncology Committee within Biocom, much the same way we did seven or eight years ago with contract research organizations, or CROs. Back then, we recognized that San Diego had enormous strength in the contract research arena and brought those members together to promote their success. Recognizing San Diego's strength in oncology, we partnered on two Cancer Moonshot Summit meetings here last year in which researchers, patients and biopharma companies discussed how to more quickly develop therapies and move them into the hands of physicians.

The strengths of the larger pharma companies focused on oncology research and development here, including Celgene, Takeda and Lilly, contribute in a big way to growing the workforce as well. And our research institutes, including Salk, Moores Cancer Center and Sanford Burnham Prebys all three NCI-designated cancer centers contribute a pipeline of both basic and clinical research that is world-class.

What types of jobs will be in demand? (Conversely are there any jobs that are not as hot?)

Based on the results from a workforce trends report the Biocom Institute worked on with CLSI, in the life science industry, we will continue to see growing demand for research scientists, particularly in the pharmaceutical sector, as well as in medical devices and equipment. Notably, disruptive advancements in big data and personalized medicine are spiking demand for skills in collecting, managing, analyzing and interpreting data. The push toward value-based health care is creating need for expanded skill sets for understanding reimbursement and the health care system.

On the device side, we will see growth in the number of engineering jobs of all types from electrical to computer engineering. In fact, the shortage of engineers has enticed the San Diego Venture Group to go to San Francisco to lure talent here.

Is there anything the Trump administration is doing or contemplating that is cause for excitement or concern in this sector?

It is too early to tell. We don't have a new FDA commissioner yet, but I am hopeful that members of the Trump administration will appreciate that the 21st Century Cures Act, which was passed by a bipartisan vote in both chambers of Congress, can only be effectively implemented if the allotted funding is received by the FDA.

Also, we would like to see the current freeze on federal employment be lifted, or see an exception for jobs such as those at the FDA that involve the health and safety of our population. I am encouraged by the reports on the recent meeting that President Trump had with PhRMA and its member executives recently in which he mentioned bringing more manufacturing jobs to the U.S., supporting innovation and looking for ways to streamline regulation. If the Trump administration is united with the industry in these areas, it will have a positive impact on biotech and medical technology in San Diego.

Anything else you'd like to add?

We're now entering a different dimension in the evolution of this industry one in which large pharma companies will depend even more on biotechnology companies to drive innovation. San Diego is known as a powerhouse of life science company formation and early stage growth, with many of these companies' cutting edge technologies positioning them for acquisition. Global biotech giants are making investments in San Diego companies and that's a great thing for our town moving forward. Even Johnson & Johnson, which has been here for more than 20 years, created an innovation center with its J-Labs containing some 40 incubated companies. It's refreshing and generous, as those companies have no direct tie back into J&J, contributing to their ability to innovate on their own.

We're seeing more incubators being created here, such as the partnership that Biocom is engaged in with another newcomer, BioLabs San Diego. I expect San Diego to grow in visibility because of this strength, along with demographic and economic advances, including the increased ease of international travelers coming to San Diego as a result of the launch of international flights this year to Frankfurt and Zurich, as well as the ability to fly directly into the Tijuana airport and cross the pedestrian bridge to the U.S.

Joe Panetta, President & CEO of Biocom

Go here to see the original:
Biotech: Full steam ahead on several scientific fronts - The San Diego Union-Tribune

Posted in Human Longevity | Comments Off on Biotech: Full steam ahead on several scientific fronts – The San Diego Union-Tribune

Ratan Tata’s investment in start-ups rises 30 per cent in fiscal 2016 – Hindu Business Line

Posted: at 6:47 pm

Mumbai, February 19:

Ratan Tatas personal investment firm RNT Associates had invested up to 80 crore in about 30 start-ups in fiscal 2016. This is 30 per cent higher than the 61-crore the company invested in FY-15.

According to the companys latest filings with the RoC, accessed by BusinessLine via business research platform Tofler, the Mumbai-based investment firm, set up by Ratan Tata in March 2009, made small ticket-size investments in the range of 25 lakh to about 5 crore on an average. However, in 2015-2016, RNT's highest investment of about 31 crore was made in a company called Human Longevity.

The San Diego-based company is creating the world's largest and comprehensive database of whole genome, phenotype and clinical data. RNT also made a small investment of 3.25 crore in the world's largest community driven hospitality start-up Airbnb. Besides, RNT Associates has also invested in venture and seed funds, including Kay Capital, Charme II and Charme III, Lets Venture, Online Pte and Seedplus Singapore.

The 79-year-old former chairman of Tata Sons has made some early stage investments in Indian unicorns such as Snapdeal, Ola and Paytm, through RNT Associates in which he holds about 99.9 per cent stake.

His close aide Krishna Kumar Kuttambally (aka KK), who was earlier his right hand man in Tata Sons, holds a very minority stake of 0.01 per cent. R Venkataramanan or Venky is also a Director on the board but has no shareholding in the company. The company has a subsidiary in Singapore, according to the RoC filing.

However, it seems that the valuations of RNT's investee companies have eroded given that the revenues and profits of the company has declined in FY-16.

RNT's consolidated revenues in 2016 stood at 6.9 crore, down by 175 per cent from 19 crore in 2015, the RoC data shows. The profits have also come down by 25 per cent at 2.7 crore in 2016 against 11 crore in the year-ago period. There is usually a lag of six months to nine months when it comes to unlisted companies filing their annual numbers with the RoC, hence fiscal numbers are available only in December to February period.

Compared to 2015, the year 2016 had remained a very challenging one for the Indian start-up ecosystem as the valuations of several heavily funded companies such as Flipkart and Snapdeal came down following markdowns by their respective investors. Many well-funded start-ups shut down and a few merged with other bigger start-ups at lower valuations, thus marking the start of consolidation period in that segment.

Many of Tata's investee companies such as Zivame, Snapdeal and Ola have seen major restructuring and reshuffle at the top management level and are facing severe cash crunch as global investors have tightened their purses. Meanwhile, a few like Bluestone and Urban Ladder are restructuring their businesses and reworking on their strategies.

(This article was published on February 19, 2017)

Please enter your email. Thank You.

Newsletter has been successfully subscribed.

See the article here:
Ratan Tata's investment in start-ups rises 30 per cent in fiscal 2016 - Hindu Business Line

Posted in Human Longevity | Comments Off on Ratan Tata’s investment in start-ups rises 30 per cent in fiscal 2016 – Hindu Business Line

Woman Proudly Shows Off Her Eczema To Prove A Point About Instagram – Huffington Post

Posted: at 6:46 pm

A picture says a thousand words, but onsocial media, they dont always tell the whole story.

Gray posted two side-by-side photos on of her face last week, calling the post a reality check. The first image, she wrote, ishow you see me when my eczema is under control, Ive done my makeup and Im feeling sassy. The second, she said, was taken when my eczema isnt under control, its very blotchy, sore and I cant wear any makeup.

Gray acknowledged that social media is a great way to show the good parts of people and their lives, but she wanted to use this image to remind her 139,000 followers that what you see on social media is not the full story, its not how that person will look or be alllllll the time!

Indeed. Eczema is common skin condition that affects over 30 million Americans. Symptoms can include redness, itching, inflammation, oozing and swelling of the skin. Promising trialsshow that relief may be on the way for some, and there are dermatologist-approved remediesand productsthat help people with eczema cope. Still, theres currently no cure.

The condition is still a big insecurity for Gray, she admits, but she said shes learning to accept myself knowing that everyone has their own struggles and insecurities and thats what makes us unique and special.

Read more:
Woman Proudly Shows Off Her Eczema To Prove A Point About Instagram - Huffington Post

Posted in Eczema | Comments Off on Woman Proudly Shows Off Her Eczema To Prove A Point About Instagram – Huffington Post

Ask the Doctors: Healthy diet can restrict psoriasis flare-ups – Chicago Sun-Times

Posted: at 6:46 pm


Chicago Sun-Times
Ask the Doctors: Healthy diet can restrict psoriasis flare-ups
Chicago Sun-Times
Dear Doctor: I've had psoriasis for close to seven years, and lately it has been flaring up more often. Is there anything I can do with my diet to control this, or even prevent it from happening? Dear Reader: That's a good question. Thanks to the ...

Go here to see the original:
Ask the Doctors: Healthy diet can restrict psoriasis flare-ups - Chicago Sun-Times

Posted in Psoriasis | Comments Off on Ask the Doctors: Healthy diet can restrict psoriasis flare-ups – Chicago Sun-Times

Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal … – Dove Medical Press

Posted: at 6:46 pm

Back to Browse Journals Psoriasis: Targets and Therapy Volume 7

Marina Agozzino,1 Cecilia Noal,2 Francesco Lacarrubba,3 Marco Ardig4

1Dermatology Unit, Second University of Naples, Naples, 2Dermatology Unit, University of Trieste, Trieste, 3Dermatology Clinic, University of Catania, Catania, 4Clinical Dermatology Department, San Gallicano Dermatological Institute, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy

Abstract: Reflectance confocal microscopy (RCM) evaluation of inflammatory skin diseases represents a relatively new technique that, during the past 5years, has attracted increasing interest, with consequent progressive increment of publications in literature. The success of RCM is directly related to the high need for noninvasive techniques able to both reduce the number of skin biopsies and support clinical diagnosis and patient management. RCM helps to visualize microscopic descriptors of plaque psoriasis (PP) with good reproducibility between observers and a high grade of correspondence with histopathology. Several clinical tests are used for the therapeutic management of PP, but they are limited by subjective interpretation. Skin biopsy presents objective interpretation, but the procedure is invasive and not repeatable. RCM has been used not only for the evaluation of skin cancer or inflammatory skin diseases, but also for monitoring the efficacy of different treatments in PP. In this review, we present some examples of RCM applications in therapeutic psoriasis follow-up.

Keywords: reflectance confocal microscopy, psoriasis noninvasive follow-up, psoriasis monitoring

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View post:
Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal ... - Dove Medical Press

Posted in Psoriasis | Comments Off on Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal … – Dove Medical Press

Espedilla: Beating Psoriasis at home (part 3) | SunStar – Sun.Star

Posted: at 6:46 pm

Espedilla: Beating Psoriasis at home (part 3) | SunStar
Sun.Star
Psoriasis would be a lot worse if you won't kick the habit of smoking. In fact, one study have shown that people who smoked more than a pack a day were twice as likely to have a serious case of psoriasis than those who smoked half a pack or less. Women ...

Read more from the original source:
Espedilla: Beating Psoriasis at home (part 3) | SunStar - Sun.Star

Posted in Psoriasis | Comments Off on Espedilla: Beating Psoriasis at home (part 3) | SunStar – Sun.Star

Gene editing could help tackle cancer and inherited diseases – Medical Xpress

Posted: at 6:46 pm

February 20, 2017 Credit: CC0 Public Domain

Gene editing techniques developed in the last five years could help in the battle against cancer and inherited diseases, a University of Exeter scientist says.

Dr Edze Westra said the ability to splice selected DNA into cells with great precision would become "super important" in the next two decades. There could be benefits for generations of people affected by cancer, failing vision and the diseases of old age or bad genes.

"There is always a risk with this kind of technology and fears about designer babies and we have started having discussions about that so we can understand the consequences and long-term risks," said Dr Westra, of the Environment and Sustainability Institute on the University of Exeter's Penryn Campus in Cornwall. "I think in the coming decades gene editing will become super important, and I think we will see it being used to cure some inherited diseases, to cure cancers, to restore sight to people by transplanting genes. I think it will definitely have massive importance."

On Tuesday, two highly influential academic bodies in the US shook up the scientific world with a report that, for the first time, acknowledged the medical potential of editing inherited genes. The National Academy of Sciences and National Academy of Medicine ruled that gene editing of the human "germline"eggs, sperm and embryosshould not be seen as a red line in medical research.

Many critics insist that powerful new gene editing techniques should never be used to alter inherited DNA. They argue that such a move would be the start of a slippery slope leading to "designer" babies with selected features such as blue eyes, high intelligence or sporting prowess.

But the two pillars of the American scientific establishment said that with necessary safeguards, future use of germline gene editing to treat or prevent disease and disability was a "realistic possibility that deserves serious consideration".

Dr Westra is taking part in a discussion on gene editing and its potential implications for society at the American Association for the Advancement of Science (AAAS) annual meeting in Boston, Massachusetts. He said gene editing technology not only held out the promise of fixing genetic faults, but could be used to turn cells into miniature factories that churned out therapeutic chemicals or antibodies.

One application was the use of "gene drives" that increase the prevalence of a certain trait in a population. For instance, gene editing machinery placed inside the cells of large numbers of malaria transmitting mosquitoes could prevent them spreading the organism that causes the disease to humans.

The most promising form of gene editing, known as CRISPR/Cas9, was first demonstrated in 2012. It employs a defence system bacteria use to protect themselves against viruses. A carefully targeted enzyme is used as chemical "scissors" that cut through specific sections of double stranded DNA. Then the cell's own DNA repair machinery can be exploited to insert the "pasted" genetic material.

Dr Westra said: "Gene editing is causing a true revolution in science and medicine because it allows for very precise DNA surgery. "A mutation in a gene that causes disease can now be repaired using CRISPR."

Explore further: No designer babies, but gene editing to avoid disease? Maybe

Gene editing techniques developed in the last five years could help in the battle against cancer and inherited diseases, a University of Exeter scientist says.

(Medical Xpress)A team of researchers with New England Biolabs Inc. (NEB) has found that sequenced DNA samples held in public databases had higher than expected low-frequency mutation error rates. In their paper published ...

Personalized medicine, which involves tailoring health care to each person's unique genetic makeup, has the potential to transform how we diagnose, prevent and treat disease. After all, no two people are alike. Mapping a ...

Work on gene therapy is showing significant progress for restoring muscle strength and prolonging lives in dogs with a previously incurable, inherited neuromuscular disease. UW Medicine Institute for Stem Cell and Regenerative ...

A genomic study of baldness identified more than 200 genetic regions involved in this common but potentially embarrassing condition. These genetic variants could be used to predict a man's chance of severe hair loss. The ...

Purdue University and Indiana University School of Medicine scientists were able to force an epigenetic reaction that turns on and off a gene known to determine the fate of the neural stem cells, a finding that could lead ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More here:
Gene editing could help tackle cancer and inherited diseases - Medical Xpress

Posted in Gene Medicine | Comments Off on Gene editing could help tackle cancer and inherited diseases – Medical Xpress

New gene drive technology could wipe out malaria, but is it safe? – Science Magazine

Posted: at 6:46 pm

New gene drive technology carries hope and risk

Caroline Davis2010 / Flickr

By Yasemin SaplakogluFeb. 19, 2017 , 12:15 PM

Q: Should we be looking at how the environment might be affected by gene drives?

A: Absolutely, this is a manipulation of nature. We dont know how it would affect population dynamics and ecosystems. In some cases, the purpose of gene drives would be to reduce population sizes of an organism, which could influence processes like pollination and transmission of parasites. In other cases, we would use gene drives to weed out disease by driving the population that carries that disease to extinction.

Q: What is the worst-case scenario of releasing these organisms?

A: Eliminating an organism or reducing its numbers greatly. By eliminating one plant species, you cause the proliferation of others, and this leads to a series of changes in the ecosystem. We need to understand the system well enough so that we can take ethical concerns into account as we make decisions.

Evolutionary ecologist James Collins

Charles Kazilek

Q: Who gets to make these decisions?

A:Social scientists are trying to come up with better ways to sample human populations to get a better sense of whats tolerable and whats not tolerable in terms of their release. . If you release [modified mosquitoes] in Town A, the mosquitoes may not have any problem flying to Town B, even though Town B is not interested in having them. Theyll go anyway.

A:The advantage of these other technologies is that they are effective only as long as youre releasing modified male mosquitoes. When you stop the manipulation, the population would bounce back to normal levels. You have a control over the system that is yet to be demonstrated for gene drives where once you alter the genes in these populations, they just keep changing.

Please note that, in an effort to combat spam, comments with hyperlinks will not be published.

Go here to see the original:
New gene drive technology could wipe out malaria, but is it safe? - Science Magazine

Posted in Gene Medicine | Comments Off on New gene drive technology could wipe out malaria, but is it safe? – Science Magazine

Editorial: A way forward in gene editing – New Haven Register

Posted: at 6:46 pm

The 1997 film Gattaca predicted a near future in which cities are powered by vast solar thermal arrays, humans launch manned missions to Saturns moons, and doctors design super smart and strong babies. A generation later, it is the gene editing that is proving most prescient.

Over the past decade, huge advances in gene-editing techniques have enabled researchers to slice up and rewrite DNA with incredible precision. At the forefront of the ensuing revolution is the CRISPR-Cas9, a technology derived from bacteria that enables scientists to snip and repair DNA, nucleotide by nucleotide, quickly and cheaply. The potential uses are vast. And so are the ethical quandaries.

The National Academies of Sciences and the National Academy of Medicine convened a panel to recommend guidelines for the use of powerful gene-editing tools. The results, released this week, are thoughtful and should for the moment, anyway channel research and testing in unambiguously positive directions.

CRISPR can be used in basic laboratory research, revealing how disease works on the molecular level. This is similar enough to other types of lab research that it requires no novel scientific or ethical standards. Researchers can also treat live humans with gene editing technologies, for example by taking immune cells out of the body, altering them and re-inserting them to fight an advanced cancer. Therapies such as these are already under development, and although researchers have to be cautious about off-target gene slicing, existing rules governing the development of medical treatments should suffice.

Advertisement

The ethics get much trickier when researchers want to change the DNA in reproductive cells, which would alter the genes that parents pass to children, forever. Doing so could prevent vast amounts of human suffering. But there is a problem of consent: Future generations have no say in their alteration. Disability communities would no doubt feel threatened and stigmatized, because gene editing could be used to essentially remove their type from the gene pool. Changes made to enhance human offspring, rather than simply to combat disease and disability, could redefine what it means to be human, while those to whom these techniques are unavailable would risk becoming a genetic underclass. A line would have to be drawn between heritable changes that are clearly valuable and those that risk unnecessarily humiliating people, destabilizing society and changing the nature of humanity.

The panel attempted to draw a preliminary line and put it in the right place. Heritable changes should be attempted only when scientists are convinced that specific genes cause or strongly predispose people to getting a serious disease or a condition, and when they know what normal genetic code should look like. They should only intervene when there are no reasonable alternatives available to families, and when real-world evidence shows that the benefits outweigh the risks.

The debate will not and should not end there. But before society has a full chance to process these questions, the panels approach is the right one. The goal should be to stop crippling diseases, not to build designer babies.

Editorial courtesy of the Washington Post.

See the original post:
Editorial: A way forward in gene editing - New Haven Register

Posted in Gene Medicine | Comments Off on Editorial: A way forward in gene editing – New Haven Register

Vitamin B3 Protects Mice from Glaucoma, Study Finds – Sci-News.com

Posted: at 6:46 pm

Vitamin B3, also known as niacin and nicotinic acid, prevents eye degeneration in glaucoma-prone mice, according to a study published in the Feb. 17 issue of the journal Science.

Williams et al show that dietary supplementation with a single molecule (vitamin B3 or NAM) or Nmnat1 gene therapy significantly reduces vulnerability to glaucoma by supporting mitochondrial health and metabolism. Image credit: Mizianitka.

Glaucoma, a group of complex, multifactorial diseases, is one of the most common neurodegenerative diseases worldwide and the most common cause of age-related blindness in the United States. There is currently no cure, and once vision is lost, the condition is irreversible.

In most glaucoma patients, harmfully high pressure inside the eye or intraocular pressure leads to the progressive dysfunction and loss of retinal ganglion cells (neuronal cells that connect the eye to the brain via the optic nerve).

Increasing age is a key risk factor for glaucoma, contributing to both harmful elevation of intraocular pressure and increased neuronal vulnerability to pressure-induced damage.

We wanted to identify key age-related susceptibility factors that change with age in the eye and increase vulnerability to disease and in particular neuronal disease, said Prof. Simon W.M. John, from the Jackson Laboratory, Tufts University of Medicine and the Howard Hughes Medical Institute.

By understanding general age-related mechanism, there is the potential to develop new interventions to generally protect from common age-related disease processes in many people.

Conducting a variety of genomic, metabolic, neurobiological and other tests in DBA/2J mice, a widely used model of chronic, age-related, inherited glaucoma, Prof. John and co-authors discovered that NAD a molecule vital to energy metabolism in neurons and other cells declines with age.

The decrease in NAD levels reduces the reliability of neurons energy metabolism, especially under stress such as increased intraocular pressure.

Like taking that big hill on your old bike, some things are going to fail more often, said Prof. John, corresponding author of the study.

The amount of failure will increase over time, resulting in more damage and disease progression.

In essence, the treatments of vitamin B3 boosted the metabolic reliability of aging retinal ganglion cells, keeping them healthier for longer.

Because these cells are still healthy, and still metabolically robust, even when high intraocular pressure turns on, they better resist damaging processes, said Dr. Pete Williams, first author of the study and a researcher at the Jackson Laboratory.

The researchers also found that a single gene-therapy application of Nmnat1 the gene for an enzyme that makes NAD from nicotinamide prevented glaucoma from developing in DBA/2J mice.

It can be a problem for patients, especially the elderly, to take their drugs every day and in the correct dose. So gene therapy could be a one-shot, protective treatment, Dr. Williams said.

Gene therapies, through injections into the eye, have been approved for a handful of very rare, human genetic eye disorders, and their demonstration of an important age-dependent factor may enable gene therapy for more common eye disease.

The authors are pursuing clinical partnerships to begin the process of testing the effectiveness of vitamin B3 treatment in glaucoma patients. They are also exploring potential applications for the treatment in other diseases involving neurodegeneration.

_____

Pete A. Williams et al. 2017. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 355 (6326): 756-760; doi: 10.1126/science.aal0092

Read more:
Vitamin B3 Protects Mice from Glaucoma, Study Finds - Sci-News.com

Posted in Gene Medicine | Comments Off on Vitamin B3 Protects Mice from Glaucoma, Study Finds – Sci-News.com

Page 2,044«..1020..2,0432,0442,0452,046..2,0502,060..»